$LABTJun 22, 2026, 12:02 PMAI processed
Lakewood-Amedex (LABT) wins Australia composition-of-matter patent for Bisphosphocin antimicrobials
AI Summary
Lakewood-Amedex (LABT) said IP Australia issued a composition-of-matter patent (issued March 5, 2026) protecting its Bisphosphocin® class of fast-acting, broad-spectrum antimicrobial compounds being developed for complicated urinary tract and pulmonary infections. The company says the grant enlarges its global IP footprint (now citing 72 granted and 29 pending patents), which could bolster exclusivity and licensing leverage, but no new clinical data or regulatory milestones were announced and the patent alone does not reduce development or commercialization risk.
Positives
- Composition-of-matter patent issued in Australia (March 5, 2026) for Bisphosphocin® compounds
- Patent explicitly covers compounds being developed for complicated UTIs and pulmonary infections
- Company reports global IP portfolio now includes 72 granted patents and 29 pending applications
Negatives
- No clinical data, trial starts, or regulatory approvals were announced with the patent
- This announcement is a jurisdictional patent grant (Australia) rather than a regulatory or commercial milestone
- Patent protection does not guarantee future product approval, safety, efficacy, or commercial success